Rapid
Regulatory Status Disclosed
Overview
RapidAI, formerly iSchemaView, offers an AI-enabled software platform designed to assist clinicians in assessing medical images. The platform is utilized across various specialties, including neurovascular, cardiac and vascular, and radiology, and is applicable in acute care settings, such as stroke centers, as well as for longer-term patient management.
- What it does: RapidAI’s platform processes and analyzes CT and MR images to provide insights that support clinical decision-making. It goes beyond basic detection to offer quantitative and contextualized information for various conditions.
- Who it is for: The tool is intended for physicians, radiologists, and care teams involved in diagnosing and managing conditions across neurovascular (e.g., ischemic stroke, ICH, aneurysms), cardiac and vascular (e.g., aortic assessment, pulmonary embolism), and general radiology. It aims to support workflows in hospitals and healthcare systems.
- How it fits a clinical or practice workflow: RapidAI integrates with existing hospital systems, including PACS, EHR, and worklist providers, to streamline radiology workflows and facilitate communication among care teams. It can automatically send images for processing and deliver results to PACS, email, and mobile apps. The platform is designed to provide real-time collaboration and alerts for urgent cases.
- Notable capabilities: Key features include deep clinical AI for detailed insights, workflow integration for seamless execution, enterprise infrastructure for scalability and security, and data analytics for performance visibility. Specific modules address neurocritical assessment, ischemic stroke, aneurysm detection and tracking, aortic assessment, and pulmonary embolism detection. The platform also offers Navigator Pro for radiology case prioritization and AI interpretation assistance.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-enabled medical imaging analysis platform
- Automated processing of CT and MRI images
- Detection of large vessel occlusion (LVO) and intracranial hemorrhage (ICH)
- CT perfusion (CTP) and MR perfusion maps
- CT angiography (CTA) maps and 3D reconstruction
- ASPECTS scoring from CT scans
- Mobile app for real-time notifications and image viewing
- Integration with PACS, email, text, and third-party systems
- Customizable notifications for hospitals and physicians
- Aneurysm and aortic analysis capabilities
Use Cases
- Acute stroke assessment and diagnosis
- Patient triage and clinical decision making in cerebrovascular emergencies
- Selection of patients for mechanical thrombectomy
- Monitoring of cerebral aneurysms
- Detection and monitoring of aortic aneurysms and dissections
- Facilitating communication and collaboration among stroke care teams
What Physicians Need to Know
Stroke Detection Speed
RapidAI analyzes CT scans in 1-6 minutes, significantly faster than traditional radiology workflows (15-60 minutes), reducing door-to-notification time by 30-52%. Specifically, Rapid LVO can detect anterior circulation LVOs in a mean average time of 3 minutes and 30 seconds. The system can flag suspected large vessel blockages within 5 minutes after CT scanning.
Brain MRI/CT Analysis
RapidAI is an AI-enabled software platform that processes and analyzes CT and MRI images to assist clinicians in assessing patients with suspected stroke. It offers a comprehensive suite of products for ischemic stroke, including Rapid NCCT Stroke, Rapid LVO, Rapid CTA, Rapid Perfusion Imaging (CTP), Rapid ASPECTS, and Rapid Hypodensity. The platform also includes modules for detecting intracranial hemorrhages (ICH) and subdural hematomas (SDH). RapidAI's deep clinical AI goes beyond simple anomaly detection to provide quantitative, contextualized insights, measuring, visualizing, and tracking disease over time. It can create color-coded maps distinguishing ischemic core from salvageable tissue.
EEG Interpretation AI
RapidAI does not appear to offer EEG interpretation AI. Other systems like Ceribell utilize AI algorithms for rapid response point-of-care EEG to identify nonconvulsive seizures within a 5-minute interval. Research is also ongoing for AI systems to identify epilepsy by analyzing brain interactions and integrating EEG electrode positions and brain regions monitored.
Seizure Detection
RapidAI's primary focus is on stroke and neurovascular conditions, and there is no information indicating it offers seizure detection capabilities. Other AI systems, such as Ceribell, are designed for rapid detection of nonconvulsive seizures using point-of-care EEG with AI algorithms. These systems can monitor seizure activity and burden.
Neurodegenerative Disease Screening
RapidAI's core offerings are centered around acute neurovascular conditions like stroke and aneurysms, with no explicit mention of neurodegenerative disease screening.
Large Vessel Occlusion Detection
RapidAI excels in Large Vessel Occlusion (LVO) detection. The Rapid LVO software has demonstrated superior accuracy, detecting 33% more LVO-positive cases than a leading competitor (98% vs. 74% sensitivity) in a large head-to-head study. It correctly identified 94% of LVO-negative cases. Rapid LVO is FDA-cleared and provides results in approximately three minutes, with a sensitivity of 97% and specificity of 96%. It can quickly detect anterior circulation LVOs with a sensitivity of 96% and specificity of 98%. RapidAI also offers an FDA-cleared NCCT imaging solution for suspected LVO, improving care equity.
Triage Prioritization Speed
RapidAI significantly improves triage prioritization by providing real-time, simultaneous alerts to the entire care team within minutes of a scan. This streamlines communication and decision-making, reducing team notification times from over 30 minutes to under 5 minutes in some settings. The Navigator Pro feature offers AI-driven worklist prioritization to ensure urgent cases are addressed first.
ASPECTS Score Automation
Rapid ASPECTS provides an automated, standardized Alberta Stroke Program Early CT Score (ASPECTS) based on machine-learning algorithms. This automation helps determine thrombectomy eligibility and quantifies early ischemic changes. Studies show that Rapid ASPECTS assistance improves the accuracy and uniformity of ASPECT scores among clinicians, increasing overall accuracy from 0.72 to 0.82. It delivers a standardized ASPECT score in less than 2 minutes. Rapid ASPECTS has FDA CADx clearance for assisting clinicians with ASPECTS assessment.
Mobile Notification System
RapidAI features a robust mobile notification system through the Rapid Mobile App. Clinicians receive instant, HIPAA-compliant notifications on their mobile devices, as well as through PACS or email. The app allows for real-time collaboration, viewing of AI outputs and source imaging in a DICOM viewer, in-app messaging, and consultation with colleagues. This system helps prepare and alert neurological staff, enabling them to view patient scans prior to arrival and plan treatment. Notifications can be customized based on clinical thresholds.
Subdural Hematoma (SDH) Detection
RapidAI provides fast and accurate detection of both acute and chronic SDH on NCCT, with a sensitivity of 92.4% and a specificity of 98.7%. The median processing time for SDH detection is approximately 45 seconds.
Physician Tip
RapidAI's deep clinical AI goes beyond simple anomaly detection, providing quantitative and contextualized insights that can significantly aid in decision-making for acute stroke cases. Leverage the automated ASPECTS scoring and perfusion maps to quickly identify salvageable tissue and determine thrombectomy eligibility, even in extended windows. Utilize the mobile app for real-time, simultaneous communication with the entire stroke team to drastically reduce notification and decision times. Remember that while AI provides rapid and accurate analysis, it serves as a powerful assistant, and final diagnostic and treatment decisions remain with the physician. Integrate the AI outputs with your clinical judgment and patient presentation for optimal outcomes. The platform's ability to track disease over time can also be valuable for longitudinal patient management.
The Rapid Enterprise™ Platform is designed for seamless integration into existing hospital IT infrastructure, including PACS, RIS, EHR systems, and communication platforms. It supports standard (HL7, FHIR, DICOM) and custom APIs, allowing for interoperability across the healthcare ecosystem. RapidAI also integrates with third-party algorithms and partner AI solutions. A notable integration is with Pulsara, which allows care teams to receive RapidAI notifications, access summary images and results within the Pulsara app, and share and communicate around these images, with direct links to the Rapid mobile app for detailed review.
Details
| Category | Neurology AI, Radiology & Imaging AI |
| Pricing | Unknown |
| Deployment | Enterprise infrastructure, integrates into existing stack |
| Training | Unknown |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Emergency Medicine, Neurology, Radiology |
Support & Reliability
| Training Provided | Unknown |
What the Web Says
RapidAI is an AI-driven medical imaging analysis platform designed to assist physicians in diagnosing and managing life-threatening neurovascular and vascular conditions, particularly stroke, intracranial hemorrhage (ICH), and pulmonary embolism (PE). It aims to improve patient outcomes by accelerating triage, transfer decisions, and treatment initiation through faster and more accurate analysis of CT images. The platform is utilized in thousands of hospitals across over 100 countries.
Overall: MixedStrengths
- Exciting and impactful technology that directly affects patient lives.
- High accuracy in detecting conditions like ICH and LVO, with superior sensitivity and specificity compared to some competitors.
- Significantly reduces crucial time intervals in stroke care and enhances workflow efficiencies.
- Facilitates faster triage, decision-making, and treatment initiation, leading to better patient outcomes.
- Offers flexibility and customization to meet specific hospital needs, with seamless integration into existing radiology workflows.
- Provides real-time notifications and mobile access to results and patient imaging, improving care team collaboration.
Limitations
- Some users report issues with the mobile app, including random stops in sending information, frequent logouts, and missed notifications.
- The impact of RapidAI on certain important clinical outcomes, such as patient harms, mortality, and health-related quality of life, is uncertain due to limited available evidence.
- The cost-effectiveness of RapidAI for stroke detection is currently unknown.
- Concerns exist regarding potential algorithmic bias, data privacy, and equitable access to AI technologies in healthcare.
- Some Reddit users express skepticism about the accuracy of marketing claims regarding the widespread adoption of similar AI radiology products.
- Employee reviews on Indeed mention a horrible executive team and a stressful work environment, with some employees experiencing mental abuse.
Based on reviews from: Indeed.com, Slashdot, NCBI Bookshelf, SourceForge, Capterra, G2, Reddit, Apple App Store, YouTube, RapidAI Website
Last updated: 2026-10-24
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Rapid
Press & Coverage
RapidAI Press Releases
RapidAI Highlights Research Depth and Industry Leadership at ISC 2026 With 28 Clinical Abstracts
RapidAI announced 28 scientific abstracts accepted at the International Stroke Conference (ISC) 2026, showcasing new clinical research on AI-driven gains in aneurysm detection, stroke interpretation, and enterprise imaging efficiency. The findings reflect the impact of their deep clinical AI delivered through the Rapid Enterpriseu2122 platform.
2026-02
RapidAI Press Releases
RapidAI and AWS Strengthen Relationship: Accelerate Global Deployment of Deep Clinical AI
RapidAI and Amazon Web Services (AWS) announced a strengthened working relationship to accelerate the global adoption and scalability of deep clinical AI in healthcare, focusing on co-development and go-to-market alignment. This collaboration aims to bring together AWS's AI infrastructure with RapidAI's clinical expertise and multimodal healthcare data.
2025-12
RapidAI Press Releases
RapidAI Extends the Reach of Deep Clinical AI with Five New FDA Clearances
RapidAI announced U.S. Food and Drug Administration (FDA) clearance for five new imaging modules: Rapid DeltaFuseu2122, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement. These clearances significantly expand the Rapid Enterpriseu2122 Platform, reinforcing RapidAI's commitment to deep clinical intelligence and seamless workflow integration.
2025-11
NeuroNews
RapidAI gains US FDA clearances for five new imaging modules
RapidAI received US FDA clearance for five new imaging modules, including Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement. These additions expand the Rapid Enterprise platform, aiming to reduce cognitive burden for radiologists and improve clinical decision-making.
2025-11
Vascular News
RapidAI earns US FDA clearance for AI-driven aortic measurement and surveillance product
RapidAI announced US FDA clearance for Aortic Management, part of Rapid Aortic, a comprehensive deep clinical AI solution for acute assessment and longitudinal management of aortic disease. This product provides AI-powered insights to identify and track aortic aneurysms, dissections, and other anomalies.
2025-11
AuntMinnie
RapidAI gets 5 new FDA clearances
RapidAI has received U.S. Food and Drug Administration (FDA) clearance for five imaging modules: Rapid DeltaFuse, Rapid LMVO, Rapid MLS, Rapid OH, and Rapid Aortic for measurement. These clearances significantly expand the company's Rapid Enterprise platform for neurology and vascular care.
2025-11
Canadian Journal of Health Technologies (Published by Canada's Drug Agency)
RapidAI for Stroke Detection and AI Implementation Review
This implementation review for AI-enabled medical devices, specifically focusing on RapidAI for stroke detection, serves as a foundational report to be tailored for each AI topic and updated with the latest developments in regulation and management of AI in Canada.
2024-11
Stroke: Vascular and Interventional Neurology - American Heart Association Journals
RapidAI Compared With Human Readers of Acute Stroke Imaging for Detection of Intracranial Vessel Occlusion
This article discusses a study comparing RapidAI with human readers for detecting intracranial vessel occlusion in acute stroke imaging, highlighting the use of LR graphs to assess the superiority of RapidAI in ruling in and out the presence of intracranial occlusion.
2024-01
Videos
Product demos, reviews, and walkthroughs for Rapid.
RapidAI | The Rapid Enterprise™ Platform
RapidAI
No FAQs available yet for this tool.
Suggest an Edit → | Report an issue
| Last Verified: 2026-04-20 | First Added: 2026-04-20